292 related articles for article (PubMed ID: 33902820)
1. Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
Patoulias D; Papadopoulos C; Doumas M
Am Heart J; 2021 Jun; 236():104-105. PubMed ID: 33902820
[No Abstract] [Full Text] [Related]
2. Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis.
Teo YN; Teo YH; Syn NL; Yoong CSY; Cheong AJY; Wee CF; Lim YC; Lee CH; Yeo TC; Chai P; Wong RCC; Lin W; Sia CH
Clin Drug Investig; 2022 Jan; 42(1):1-16. PubMed ID: 34797518
[TBL] [Abstract][Full Text] [Related]
3. Cause and duration of heart failure may impact on the response to sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Mandal AKJ; Missouris CG
J Cardiovasc Med (Hagerstown); 2021 Mar; 22(3):233-234. PubMed ID: 32925393
[No Abstract] [Full Text] [Related]
4. [Sacubitril-valsartan should also be the first choice to be evaluated in the elderly patient with heart failure with reduced ejection fraction].
Camafort M; Formiga F
Rev Esp Geriatr Gerontol; 2021; 56(2):67-68. PubMed ID: 33526274
[No Abstract] [Full Text] [Related]
5. Commentary to Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
Buonacera A; Stancanelli B; Malatino L
High Blood Press Cardiovasc Prev; 2021 Jul; 28(4):331-332. PubMed ID: 33905096
[No Abstract] [Full Text] [Related]
6. Heart Failure with Preserved Ejection Fraction: Management Guidelines (From Heart Failure Association of India, Endorsed by Association of Physicians of India).
S H; Oomman A; Jadhav UM; Raghuraman B; Mohanan PP; Tiwaskar M; Wander GS; Chopra VK
J Assoc Physicians India; 2022 Aug; 70(8):11-12. PubMed ID: 36082729
[TBL] [Abstract][Full Text] [Related]
7. Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy.
Norre T; Grimm D; Simonsen U
Basic Clin Pharmacol Toxicol; 2022 Apr; 130(4):425-438. PubMed ID: 35128801
[TBL] [Abstract][Full Text] [Related]
8. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence.
Volpe M; Bauersachs J; Bayés-Genís A; Butler J; Cohen-Solal A; Gallo G; Deichl AS; Khan MS; Battistoni A; Pieske B; Saito Y; Zieroth S
Int J Cardiol; 2021 Mar; 327():138-145. PubMed ID: 33301829
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
Volpe M; Gallo G
Eur Heart J; 2021 Sep; 42(36):3753-3755. PubMed ID: 34392358
[No Abstract] [Full Text] [Related]
12. Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril-valsartan: does money matter?
Cavallari I; Maddaloni E; Grigioni F
Eur J Prev Cardiol; 2021 Dec; 28(15):1670-1672. PubMed ID: 33624108
[No Abstract] [Full Text] [Related]
13. Are Post Hoc Analyses on Subgroups Sufficient to Support New Treatment Algorithms of Heart Failure? The Case of SGLT2 Inhibitors Associated with Sacubitril/Valsartan.
Volpe M; Gallo G; Zieroth S
Cardiology; 2022; 147(1):23-25. PubMed ID: 34587618
[TBL] [Abstract][Full Text] [Related]
14. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
16. When and for Whom Should We Use SGLT2 Inhibitors in HFrEF?
Tanaka A; Node K
JACC Heart Fail; 2020 Dec; 8(12):1056. PubMed ID: 33272386
[No Abstract] [Full Text] [Related]
17. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
18. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril-valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction.
Passino C; Sciarrone P; Vergaro G; Borrelli C; Spiesshoefer J; Gentile F; Emdin M; Giannoni A
Int J Cardiol; 2021 May; 330():112-119. PubMed ID: 33581182
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
